Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.
Dionysis Papadatos-PastosWei YuanAbhijit PalMateus CrespoAna FerreiraBora GurelToby ProutMalaka AmeratungaMaxime Chénard-PoirierAndra CurceanClaudia BertanChloe BakerSusana MirandaNahal MasrourWentin ChenRita PereiraInes FigueiredoRicardo MorillaBen JenkinsAnna ZachariouRuth RiisnaesMona ParmarAlison TurnerSuzanne CarreiraChristina YapRobert BrownNina TunariuUdai BanerjiJuanita LopezJohann de BonoAnna R MinchomPublished in: Journal for immunotherapy of cancer (2022)
Guadecitabine in combination with pembrolizumab is tolerable with biological and anticancer activity. Reversal of previous resistance to immune checkpoint inhibitors is demonstrated.